Edition:
United States

Nivalis Therapeutics Inc (NVLS.OQ)

NVLS.OQ on NASDAQ Stock Exchange Global Market

8.21USD
4:00pm EDT
Change (% chg)

$-0.07 (-0.85%)
Prev Close
$8.28
Open
$8.33
Day's High
$8.50
Day's Low
$7.92
Volume
5,564
Avg. Vol
13,674
52-wk High
$13.75
52-wk Low
$3.68

NVLS.OQ

Chart for NVLS.OQ

About

Nivalis Therapeutics, Inc. is a clinical-stage pharmaceutical company. The Company discovers, develops and commercializes product candidates for patients with cystic fibrosis (CF). It focuses on utilizing its S-nitrosoglutathione reductase (GSNOR) inhibitor portfolio to develop therapeutics for other diseases. It operates... (more)

Overall

Beta: --
Market Cap(Mil.): $128.37
Shares Outstanding(Mil.): 15.50
Dividend: --
Yield (%): --

Financials

  NVLS.OQ Industry Sector
P/E (TTM): -- 47.83 37.57
EPS (TTM): -1.87 -- --
ROI: -35.37 -0.24 13.91
ROE: -35.37 -3.63 14.85

BRIEF-Nivalis Q2 loss per share $0.55

* Nivalis therapeutics reports second quarter 2016 financial results

Aug 01 2016

BRIEF-Nivalis Therapeutics completes enrollment for Phase 2 study of N91115

* Nivalis Therapeutics announces completion of enrollment in Phase 2 study of N91115 for treatment of cystic fibrosis

Jul 07 2016

BRIEF-Nivalis Therapeutics files for mixed shelf of up to $142.5 mln - SEC filing

* Says files for mixed shelf of up to $142.5 million - SEC filing Source:(http://bit.ly/29xPQCz ) Further company coverage: (Bengaluru Newsroom: +1 646 223 8780)

Jul 06 2016

BRIEF-Nivalis Therapeutics reports Q1 loss per share $0.51

* Nivalis therapeutics reports first quarter 2016 financial results

May 02 2016

Earnings vs. Estimates

Analyst Research Reports

Report Title Price
Provider : Thomson Reuters Stock Report
$25.00
Provider : ValuEngine, Inc.
$25.00
Provider : Pechala's Reports
$25.00
Provider : Reuters Investment Profile
$20.00
Provider : Ford Investor Services, Inc.
$12.00

NYSE and AMEX quotes delayed by at least 20 minutes. NASDAQ delayed by at least 15 minutes. For a complete list of exchanges and delays, please click here.